Completed Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens NCT02714595 Conditions Bloodstream Infections (BSI), Complicated Urinary Tract Infection (cUTI), Cross Infection, +17 more Locations Shionogi Research Site — Hartford, Connecticut, United States Shionogi Research Site — Newark, Delaware, United States Shionogi Research Site — Chicago, Illinois, United States Shionogi Research Site — New Orleans, Louisiana, United States View all 85 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens NCT03032380 Conditions Cross Infection, Disease Attributes, Healthcare-Associated Pneumonia, +12 more Locations Shionogi Research Site — New Haven, Connecticut, United States Shionogi Research Site — DeLand, Florida, United States Shionogi Research Site — Chicago, Illinois, United States Shionogi Research Site — Council Bluffs, Iowa, United States View all 119 locations View more locations Show fewer locations Loading locations... View Trial Details
